Current autotransfusion machines only allow the patient’s red blood cells to be saved. This is an important limitation since it means that transfusions of allogeneic platelet transfusions are still needed in the event of massive bleeding.
.i-SEP is developing a new generation of intraoperative cell salvage technology (IOCS), capable of recovering not only red blood cells but also the patient’s platelets.
Promising preclinical results for patients and physicians
i-SEP already draws on preclinical results obtained in collaboration with its academic and hospital partners, including the Bordeaux and Rennes University Hospitals and the ONIRIS veterinary school.
For physicians, same™ differs first and foremost in its ergonomics and intuitiveness. The equipment is designed for immediate deployment and faster installation. Having fast blood treatment is also important since this limits the risk of hemorrhagic shock for the patient and same™ treats blood faster than the average of competitive alternative techniques.
Preserving platelets and their haemostatic competence
The innovative process developed by i-SEP offers a red blood cell yield equivalent to competing techniques, i.e. approximately 90%.
Our innovation lies in our ability to recover between 53% to 81% of platelets, compared to only 5% to 11% for competing centrifugation techniques. These figures are critical given the cost and risks associated with the transfusion of allogeneic platelet concentrates.
Access to the page is reserved to health professionals
not for sale in USA